Castle Biosciences (CSTL) Insider Maetzold Sells $463K of Stock
Key Points
- Castle Biosciences CEO Derek J Maetzold sold 14,496 shares at $31.91 each on October 19, 2026, totaling roughly $462,567.
- After the trade, Derek J Maetzold holds 12,484 $CSTL shares, down 53.73% from before the trade.
- Institutional funds including RTW Investments and Acadian Asset Management recently adjusted their holdings in the molecular diagnostics firm.
- Castle Biosciences shares recently traded around $33.15, ahead of the company's next earnings report scheduled for November 5, 2026.
Since the trade, $CSTL is up 6.8% to date (from the $32.17 close on Oct 19, 2026).
Get Castle Biosciences text alerts
We text you when insiders, Congress, analysts or big funds move on $CSTL.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Castle Biosciences, Inc. alert may contain errors. Disclosures
Castle Biosciences, Inc. President and Chief Executive Officer Derek J Maetzold sold 14,496 shares of the company on October 19, 2026. According to a Form 4 filed with the SEC, the shares were sold at a price of $31.91 in a pre-arranged transaction, bringing the total value to about $462,567.
CSTL
Castle Biosciences, Inc.
Inside Derek J Maetzold's CSTL Trade
The planned sale lowered Maetzold's direct holdings down to 12,484 shares. This reduction represents about a 53.7% drop in his personal share count in the diagnostic test provider. On the day of the transaction, Castle Biosciences stock closed at $32.17.
Other Institutional Activity in Castle Biosciences
Large investors have made several adjustments to their positions in the diagnostic firm. RTW Investments grew its holdings by 20,135 shares, ending with 2,778,335 shares worth about $95.5 million. Principal Financial Group, Inc. reduced its stake by 43,184 shares, leaving it with 1,726,648 shares valued at roughly $59.3 million. Meanwhile, Acadian Asset Management LLC expanded its position by adding 434,215 shares, bringing its total to 918,668 shares worth about $31.6 million.
Castle Biosciences, Inc. Stock Holds Steady
The stock recently traded around $33.15, sitting about 3.0% higher than its event-day close and roughly 15.4% above its 200-day moving average.
Recent Earnings
Castle Biosciences reported trailing twelve month revenue of $357.3 million alongside an EPS of -$0.64. The company has its next earnings report scheduled for November 5, 2026.
Insider Buying and Selling at Castle Biosciences, Inc.
Insider activity has been steady in recent months. Earlier executive sales included transactions by Chief Operating Officer Kristen M Oelschlager and Chief Commercial Officer Tobin W Juvenal prior to this filing.
Analysts Set New Price Targets
Wall Street firms maintain an overall positive view on the stock with a consensus strong buy rating and a mean price target of $45.22 across nine analyst opinions.
About Castle Biosciences
Based in Friendswood, Texas, Castle Biosciences develops and provides specialized diagnostic and test solutions focused on dermatologic cancers, Barrett's esophagus, and other medical conditions. The firm works to provide physicians with actionable genetic information to guide personalized treatment choices for patients.
Bottom Line
Investors will look toward the upcoming November 5 earnings release for further details on revenue growth and financial progress. No investment advice is implied by these regulatory filings.
Related Filing Alerts
Source: Derek J Maetzold's Form 4 filing on $CSTL (Oct 19, 2026). Written by software, not financial advice. How we make alerts